跳至主要内容
临床试验/NCT03672357
NCT03672357尚未招募不适用

Short and Long Outcomes Between Laparoscopic and Open Hepatectomy

hui hou1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2019年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
80
试验地点
1
主要终点
Change of serum glutamic oxalacetic transaminase

研究概览

简要总结

LLR was applied for tumors located at the lower edge and lateral segments of the liver that could be resected more easily than posterosuperior segments. With the development of technology and the growing experience of hepatobiliary surgeons, LLR has been expanded to major liver resections, anatomical resections, and donor hepatectomies by skilled surgeons. However, due to the concerns over the risk of operative bleeding, tumor seeding and positive resection margin, the true benefit of LLR remains unclear across surgical community.

详细描述

The 2nd International Consensus Conference on Laparoscopic Liver Resection (ICCLLR) was held in Morioka, Japan, in 2014. The new recommendations of the ICCLLR state that the outcomes of LLR are not inferior than OLR regarding to operative mortality rate and margin negativity, and are superior in decreasing postoperative complications, blood loss, and the length of the postoperative hospital stay. However, it is not clear that whether LLR is able to alleviate the impairment of liver function after hepatic resection, and there is no RCTs to compare the short and long outcomes between LLR and OLR.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient who underwent hepatectomy for benign or malignant neoplasm of the liver, and is suitable for both open and laparoscopic liver resection;
  • Child-Pugh A without portal hypertension
  • No portosystemic shunt
  • No previous abdominal operation history.
  • American society of anesthesiology class(ASA): I or II
  • Age 18 to 80

排除标准

  • Additional intervention to the liver (Radio Frequent Ablation, Percutaneous Ethanol. Injection Therapy or others)
  • Combined hepatectomy
  • Intrahepatic duct stone disease
  • Liver disease caused splenomegaly
  • Previous hepatectomy
  • Combined operation for extrahepatic disease
  • Vulnerable population (mental retardation, pregnancy)

研究组 & 干预措施

Laparoscopic liver resection

Experimental

Laparoscopic hepatectomy

干预措施: Laparoscopic liver resection (Procedure)

Open liver resection

Other

Open hepatectomy

干预措施: Open liver resection (Procedure)

结局指标

主要结局

Change of serum glutamic oxalacetic transaminase

时间窗: up to 7 days after liver resection

Change of serum glutamic oxalacetic transaminase after liver resection.These values will be recorded preoperative, and postoperative day-1,3,5,7.

Change of serum glutamic-pyruvic transaminase

时间窗: up to 7 days after liver resection

Change of serum glutamic-pyruvic transaminase after liver resection.These values will be recorded preoperative, and postoperative day-1,3,5,7.

次要结局

  • Postoperative complication(Rates in different grades)(up to 30 days after liver resection)
  • Mortality rates(up to 30 days after liver resection)
  • Hospital duration after operation (days)(up to 30 days after liver resection)
  • Intensive care unit stay (days)(up to 7 days after liver resection)
  • Blood transfusion (times and units)(intraoperative)
  • Duration of nasogastric tubes (hours)(up to 14 days after liver resection7)
  • Duration to first flatus (days)(up to 14 days after liver resection)
  • Resection margin status(up to 30 days after liver resection)
  • Operation time(min)(up to 30 days after liver resection)
  • Blood loss(ml)(up to 30 days after liver resection)
  • Duration of abdominal drain (days)(up to 14 days after liver resection)
  • Comfort questionnaire measures (GCQ) measures by Kolcaba(up to 7 days after liver resection)
  • Readmission rate(up to 30 days after liver resection)
  • C-reactive protein (mg/mL)(up to 5 days after liver resection)
  • Disease recurrence rates(up to 5 years)
  • Overall survival time (month)(up to 5 years after operation)
  • Disease free survival time (month)(up to 5 years after operation)

研究者

发起方
hui hou
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

hui hou

Director of the hepatobiliary surgery department

The Second Hospital of Anhui Medical University

研究点 (1)

Loading locations...

相似试验

Short and Long Outcomes Between Laparoscopic and... | 临床试验